Neurizon Therapeutics Reports Preclinical Findings for NUZ-001 in Neurodegenerative Disease
Neurizon Therapeutics Limited (ASX: NUZ) has reported new preclinical findings for NUZ-001, its lead compound for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The data demonstrates that NUZ-001 activates multiple protein clearance pathways, including autophagy and the Ubiquitin-proteasome system, both essential for removing aggregated proteins in neurons. This dual activation enhances the ability of neurons to handle misfolded or aggregated proteins, a critical process disrupted in ALS and similar diseases.
The preclinical results suggest that NUZ-001’s multi-pathway activity could provide a more effective treatment compared to therapies targeting a single pathway. The findings strengthen the scientific basis for NUZ-001 and contribute to its ongoing evaluation in the HEALEY ALS Platform Trial.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Neurizon Therapeutics Reports Preclinical Findings for NUZ-001 in Neurodegenerative Disease
Neurizon Therapeutics Limited (ASX: NUZ) has reported new preclinical findings for NUZ-001, its lead compound for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The data demonstrates that NUZ-001 activates multiple protein clearance pathways, including autophagy and the Ubiquitin-proteasome system, both essential for removing aggregated proteins in neurons. This dual activation enhances the ability of neurons to handle misfolded or aggregated proteins, a critical process disrupted in ALS and similar diseases.
The preclinical results suggest that NUZ-001’s multi-pathway activity could provide a more effective treatment compared to therapies targeting a single pathway. The findings strengthen the scientific basis for NUZ-001 and contribute to its ongoing evaluation in the HEALEY ALS Platform Trial.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au